Seronegative lupus membranous nephropathy

Mandya Chikkalingaiah Kiran

ABSTRACT

Introduction: Lupus nephritis represents the greater part of systemic lupus erythematosus (SLE) involvement. Antinuclear antibody (ANA) is positive in more than 95% of SLE population. Literature depicts the prevalence of ANA negativity around 1–5% and more prevalent in young females as seropositive lupus. Existence of full-house nephropathy is generally associated with lupus nephritis.

Case Report: We present a case of full-house nephropathy in a 24-year-old female patient with negative serology for SLE presenting with nephrotic syndrome. Renal biopsy revealed tubuloreticular inclusions (TRIs) in endothelial cells differentiating itself from rarer C1q nephropathy. Patient had partial response with conventional immunotherapy with mycophenolate mofetil (MMF) and prednisone.

Conclusion: The role of B cell depleting therapy in seronegative lupus; this population needs to be explored in future.
Seronegative lupus membranous nephropathy

Mandya Chikkalingaiah Kiran

ABSTRACT

Introduction: Lupus nephritis represents the greater part of systemic lupus erythematosus (SLE) involvement. Antinuclear antibody (ANA) is positive in more than 95% of SLE population. Literature depicts the prevalence of ANA negativity around 1–5% and more prevalent in young females as seropositive lupus. Existence of full-house nephropathy is generally associated with lupus nephritis. Case Report: We present a case of full-house nephropathy in a 24-year-old female patient with negative serology for SLE presenting with nephrotic syndrome. Renal biopsy revealed tubuloreticular inclusions (TRIs) in endothelial cells differentiating itself from rarer C1q nephropathy. Patient had partial response with conventional immunotherapy with mycophenolate mofetil (MMF) and prednisone. Conclusion: The role of B cell depleting therapy in seronegative lupus; this population needs to be explored in future.

Keywords: Full house nephropathy, Lupus nephritis, Seronegative lupus, Tubuloreticular inclusions

INTRODUCTION

Systemic lupus erythematosus (SLE) renal involvement is referred to as ‘lupus nephritis’ and is generally associated with antinuclear antibody (ANA) positivity. Antinuclear antibody is negative in approximately 5% of patients diagnosed with SLE. The existence of full-house nephropathy is generally associated with lupus nephritis. We present an interesting case of nephrotic syndrome with full house nephropathy with persistent negative lupus serology.

CASE REPORT

A 24-year-old Caucasian woman presented with swelling of feet and face since 2–3 months. On referral visit she was examined for proteinuria. Patient denies joint pain, rashes, oral ulcer, hair loss and usage of NSAIDS. Workup revealed nephrotic range proteinuria 5.51 grams per day, serum creatinine 1.2 mg/dl and urinalysis of occasional RBC, with no active sediments. Serology tests for ANA, double stranded DNA <5 IU/ml (normal 0–9), smith antibody <0.2 IU/ml (normal 0–9),
hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), rheumatoid factor and A1c were negative. Serum complement levels were within normal limits [C3 152 mg/dl (normal 90–180 mg/dl), C4 24 mg/dl (normal 9–36 mg/dl)]. Renal biopsy (34 glomeruli) revealed immune complex mediated glomerulonephritis (GN) with marked glomerular basement membrane duplication and interstitial fibrosis (5–10%) (Figure 1). Immune deposits were present in all compartments. There was no evidence of proliferative, amyloidosis, diabetic or paraproteinemia nephropathy. Immunofluorescence (IF) of nine glomeruli featured IgG3+ (Figure 2), IgA1+, IgM1-2+, C3 2+, C1q 2+ staining with absent monoclonal element. Electron microscopy of three glomeruli showed loops of sub epithelial (98%), sub endothelial (20%), mesangial (1-2+) deposits with diffuse foot process effacement. Numerous TRIs within endothelial cell cytoplasm were also seen (Figure 3). Patient was treated with MMF, prednisone, ace inhibitor (ACEI) and statin. Two weeks later patient developed severe arthritis involving both shoulder and left hip. Patient was hospitalized for intravenous steroids and repeat lupus serology were negative. Arthritis settled down and she was continued on above medications. At two year follow-up her proteinuria has improved from 5.51 to 1.1 gram per day (Figure 4) with stable renal function (Scr 1.1 mg/dl). Repeat lupus serology is negative and complement levels are normal. No lupus flares were seen in these two years. We did not have opportunity to test anti C1q antibodies in our patient.

**DISCUSSION**

Lupus nephritis represents about 50% of SLE population. Existence of ‘full house nephropathy’ defined as the presence of IgG, IgA, IgM, C1q and C3 deposits at the same time on the IF examination is generally associated with lupus nephritis [1, 2]. Full-house nephropathy can also be seen in clinical conditions such as post hepatic cirrhosis, diabetic nephropathy, membranous nephropathy, membranoproliferative glomerulonephritis and C1q nephropathy [3]. Wen et al. observed non lupus full house nephropathy in 24 patients without endothelial TRIs. Their clinicopathological spectrum included membranous glomerulonephritis (46%), IgA nephropathy (21%), membranoproliferative GN (12.5%), Post infectious GN (12.5%), C1q nephropathy (4%), and unclassified mesangial glomerulonephritis (4%) [4]. Our patient too had full house nephropathy with immune mediated glomerulonephritis, with endothelial tubuloreticular inclusion bodies.

C1q nephropathy is often reported as seronegative lupus nephritis due to under recognition. C1q nephropathy is an uncommon pathological entity accounting for 0.4–
2.0% of all consecutive native kidney biopsies [5–7]. The distinguishing characteristics of C1q nephropathy are robust staining of C1q on immunofluorescence, absence of endothelial cell TRIs [8] and anti C1q antibodies [9]. Even though our index patient had C1q 2+ on IF, the presence of TRIs with sub endothelial deposits excludes C1q nephropathy. Anti C1q antibody could not be tested on our patient.

The presence of TRIs in endothelial cells always evokes suspicion of an association with underlying viral infections or autoimmune diseases. Lee et al. studied 104 renal biopsies for TRIs expression. Lupus nephritis represented 60% whereas viral infections of HBV, HCV and HIV were 19%. TRIs were also seen in membranous glomerulonephritis (7%), IgA nephropathy (7%) and Henoch-Schonlein purpura (2%) [10]. In spite of strong association of TRIs with lupus nephritis, its presence in seronegative pathological situations like our patient can be expected.

Seroconversion from negative to positive lupus serology over years follow-up has been reported in the literature. Cairns et al. reported 11 patients of whom four developed overt lupus over 1–7 years of follow-up [11] and Adu et al., reported 17 patients of whom five developed definite evidence of lupus over 1–10 years follow-up [12]. In contrast, Jones and Maggil described five patients who remained seronegative lupus over a five-year follow-up [13]. Similarly Enriquez et al. [14] described three children who remained seronegative over short follow-up of two years. Our patient shows no seroconversion at two years follow-up. Does the seroconversion over years determine the clinical outcome, needs to be explored. What's the importance of differentiation of C1q nephropathy from full house nephropathy with or without serology positiveness? The immunosuppressive therapy response of C1q nephropathy is dismal. Immunological response of seronegative lupus matches with that of seropositive lupus. These seronegative patients with full house nephropathy and TRIs should be treated as seropositive lupus nephritis [15]. Our index case showed partial response with reduction of proteinuria from 5.5 to 1.1 g/d with MMF and prednisone. The follow-up will determine the response and renal survival.

**CONCLUSION**

We conclude that high index of suspicion and ruling out rarer pathological entities like C1q nephropathy is needed. So far immunosuppressive therapies have shown good response in seronegative lupus nephropathy. The future will underscore the role of other immunosuppressive armamentarium including anti-CD 20 monoclonal antibody (rituximab) and needs to be explored.
**Author Contributions**
Mandya Chikkalingaiah Kiran – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

**Guarantor**
The corresponding author is the guarantor of submission.

**Conflict of Interest**
Authors declare no conflict of interest.

**Copyright**
© 2016 Mandya Chikkalingaiah Kiran. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

**REFERENCES**

Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.